Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Shigella Sonnei Vaccine (1790GAHB) in Healthy Adults
NCT02034500Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2014
- Primary completion
- Apr 2015
- Modality
- Lipid-based Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GVGH Shigella sonnei 1790GAHB vaccine in shigellosis (10 arms), sponsored by GSK. Primary endpoints: Number of subjects with solicited local reaction after any vaccination, Number of subjects with solicited systemic reaction after any vaccination and 1 more. Started Mar 2014; status: completed.
02
Drugs
GVGH Shigella sonnei 1790GAHB vaccine
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT02034500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034500.